Since more than 15 years we are developing and manufacturing retroviral vectors for clinical supply. Check out what we can do for you.
BioNTech IMFS supports you in the development and industrialization of your cell-based therapy product: fast, safe and efficient.
We manufacture GMP grade IVT mRNA that can be used either as a drug product for in vivo use or as starting material for ex vivo applications.
Explore how we ensure that your technology is transferred in an efficient and timely manner and with a particular attention to quality.
Process development for innovative new drugs is a complex task, requiring customized solutions for each product.
Our experienced analytical team offers customized assay development based on cell biology, virology, molecular biology, and microbiology technologies.
We have established robust GMP manufacturing processes for a variety of different retroviral vectors, cells and mRNA products. Learn more about our clinical and commercial supply capabilities.
Our QC team ensures quality, safety and batch-to-batch consistency of all manufactured products. We have established more than 50 assays for the characterization of our customers' products.
Learn how our QA team provides directions throughout each customer project to ensure quality and regulatory compliance of all products.
To prepare for further growth in demand for cell and gene therapy products, e.g. for CAR-T and T-Cell immunotherapies, BioNTech Innovative...
September 18, 2017
BioNTech AG, announced on October 1st, 2017 that its manufacturing subsidiary EUFETS GmbH has been re-branded BioNTech Innovative Manufacturing...
EUFETS, now BioNTech IMFS, celebrates twenty years of uninterrupted service to the cell and gene therapy community. When our company was founded in...